Skip to content
    ENOV
    Earnings call· Jun 2026(Q2 FY26)

    Enovis Q2 FY26 earnings call ENOV

    Aug 6, 2026 Source

    Executive summary

    Enovis Q2 FY26 — Strong Organic Growth and Margin Expansion Despite Headwinds

    Enovis delivered robust Q2 FY26 results, driven by strong organic growth in Recon and P&R segments, alongside significant adjusted gross margin expansion. The company reaffirmed its full-year guidance, navigating headwinds from international conflicts and inflation through operational productivity and new product scaling. Management emphasized continued focus on commercial execution, innovation, and financial discipline, including debt reduction and free cash flow generation, while evaluating future portfolio advancements.

    Highlights

    5

    • Delivered 5% organic growth company-wide in Q2 FY26.

    • US Recon segment grew 6% organically in Q2 FY26, led by 8% organic growth in hips and knees.

    • Adjusted gross margins expanded to 62% in Q2 FY26, an underlying improvement of 120 basis points.

    • Adjusted earnings per share reached $0.90, representing 14% underlying growth in Q2 FY26.

    • Free cash flow improved by $27 million year-over-year to $31 million in Q2 FY26.

    Concerns

    5

    • International business negatively impacted by Middle East conflict, resulting in a 100 basis point headwind to international growth and 40 basis points to total company growth in Q2 FY26.

    • Experienced $4 million of ongoing tariff impact and $2 million of unplanned inflationary pressure in Q2 FY26.

    • Expect a $10 million full-year impact from the increased inflationary environment in FY26.

    • Noted softer markets in Western Europe (France, Spain, Italy) due to environmental factors in Q2 FY26.

    • Anticipate Q3 FY26 to have a heavier impact by seasonality than in prior years due to market conditions and Middle East conflict.

    Guidance & targets

    5
    CategoryTargetConfidence
    Full-year 2026 Guidance
    Reaffirmed
    high materiality
    High
    Free Cash Flow Conversion
    greater than 25%
    high materiality
    High
    Q3 Seasonality Impact
    heavier impact by seasonality than in prior years
    medium materiality
    Medium
    Q4 Sales Acceleration
    sales acceleration across both segments
    medium materiality
    Medium
    Leverage Ratio
    below 3x
    high materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Recon
    Strong performance driven by hips and knees in the US and double-digit growth in international shoulders. Nebula and Arvis are key growth drivers.
    US Recon organic growth: 6%Hips and Knees organic growth: 8%International Recon organic growth: 6%Shoulders growth: double-digitNebula new instrumentation sets to competitive users: >80%Arvis: full commercial launch in US
    		—6% organic——
    P&R
    Growth driven by global bracing and strong performance in Recovery Sciences and Bone Stim. New products are expected to contribute more in the latter part of the year.
    Global Bracing growth: 4%US Bracing growth: mid-single-digitRecovery Sciences and Bone Stim growth: mid-to-high single-digit
    		—3% organic——

    Operational metrics

    8
    Days Adjusted Organic Growth
    4%
    Q2 FY26

    Enterprise-level days adjusted organic growth for the second quarter.

    Adjusted Gross Margin
    62%120 bps underlying improvement
    Q2 FY26

    Underlying improvement driven by product mix and operational productivity, partially offset by tariff and inflationary impacts.

    Adjusted EBITDA Margin
    17.9%70 bps underlying improvement
    Q2 FY26

    Underlying improvement in EBITDA margin for the quarter.

    Effective Tax Rate
    24%
    Q2 FY26

    The effective tax rate for the second quarter.

    Inflationary Impact
    $10M
    FY26

    Expected full-year impact from the increased inflationary environment, primarily affecting the P&R business.

    R&D Investment
    stepped up
    FY26

    Increased investment in R&D to support future growth and innovation.

    Adjusted Costs
    stepping down
    FY26

    Costs related to the Lima integration are expected to continue to decrease.

    International Business Headwind
    40 bps
    Q2 FY26

    Impact of the Middle East conflict on total company growth in Q2.

    Industry KPIs

    7
    MetricValueDetails
    Tariff impact$8MUSD
    New product launch rampFull commercial launch
    FCF conversion leverage guidance>25%%
    Installed base system placements80%%
    Segment franchise organic growth5%%
    Sales force commercial capacity buildSufficient
    Indicated addressable patient population4-6%%

    Product announcements

    2
    ProductTypeDetails
    Arvislaunch
    Revital treatmentlaunch

    Deals & partnerships

    1
    Dr. ComfortDivestiture of the Dr. Comfort business.

    The divestiture of Dr. Comfort resulted in a headwind to reported growth for the quarter, reflecting a strategic shaping of the portfolio.

    Risks & headwinds

    6
    Middle East conflict impact on international businessQ2 FY26, ongoing

    100 bps headwind to international recon growth, 40 bps headwind to total company growth in Q2 FY26.

    Mitigation: Focus on commercial execution, account conversions, and market share gains to get ahead of potential impacts. Monitoring potential reorientation of funding towards military spend versus healthcare.

    Ongoing tariff impactQ2 FY26, ongoing

    $4 million in Q2 FY26.

    Mitigation: Actively working to mitigate, but balancing price increases with potential revenue risk, especially in the P&R business.

    Unplanned inflationary pressureQ2 FY26, full-year FY26

    $2 million in Q2 FY26, expected $10 million full-year impact for FY26.

    Mitigation: Implementing mitigation efforts, trying to pass through price increases where possible, focusing on productivity.

    Softer markets in Western EuropeQ2 FY26, potentially ongoing

    Not quantified, described as 'slightly softer market' in France, Spain, Italy.

    Mitigation: Believed to be transient (strikes, fires, heat waves) causing delays in procedures rather than cancellations. Focusing on commercial execution and market share gains.

    Increased seasonality impact in Q3Q3 FY26

    Heavier impact by seasonality than in prior years.

    Mitigation: Offsetting with benefits from commercial execution, new product scaling, and continued penetration of Nebula and ARG.

    US market noise from policy proposalsOngoing

    Not quantified, described as 'some noise'.

    Mitigation: Monitoring physician payment proposals and CJRX, but overall US markets are seen as stable.

    What to watch in Q3 FY26

    5

    Q3 Seasonality Impact on Sales

    next quarter
    CurrentExpected to be heavier than prior years
    TargetActual impact on Q3 sales growth

    Why it matters

    This will indicate the effectiveness of mitigation strategies against market conditions in Western Europe and the Middle East conflict.

    In terms of quarterly phasing📎 for the second half, we expect the third quarter to have a heavier impact by seasonality than in prior years due to market conditions in Western Europe and the continued disruption from the conflicts in the Middle East.

    Q&A highlights

    6

    Can you elaborate on the dynamics in US Recon, particularly the softer extremities growth in Q2 compared to hips and knees, and expectations for the rest of the year?

    Management clarified that H1 extremities growth was strong at 8%, similar to hips and knees. Q2 softness was attributed to a tough comp from the prior year's ARG launch and numerous medical education events that took high-volume surgeons out of the market. They expect continued momentum in H2 with ARG and Arvis expansion.

    “The Q2, yes, we had some challenges there with a few things. One is we're lapping the ARG launch from last year. So it was a pretty tough comp. But I think importantly, we had a lot of med ed events in Q2 that took a lot of our high volume KOLs and surgeons out of the space for a few weeks.”

    asked by Ryan Zimmerman · answered by Unknown Speaker

    2 min read6 chapters

    Detailed Narrative

    01

    Q2 Performance and Segment Drivers

    Enovis delivered 5% organic growth in Q2 FY26, with reported sales of $583 million. The Recon segment led with 6% organic growth, driven by strong performance in US hips and knees (8% organic growth) and international shoulders (double-digit growth). The P&R segment grew 3% organically, supported by global bracing (4% growth) and mid-to-high single-digit growth in Recovery Sciences and Bone Stim. The company noted a 4% days-adjusted organic growth at the enterprise level.

    02

    Innovation and Product Momentum

    Innovation remains a core pillar, with Nebula continuing to drive growth in hips and knees, with over 80% of new instrumentation sets going to competitive users. The Arvis platform moved into full commercial launch in the US in Q2, receiving positive early feedback for its versatility and suitability for complex shoulder anatomy. New products in P&R, including the Revital treatment in the companion market, are expected to contribute more significantly in the latter half of the year, supporting continued market share gains.

    03

    Operational Excellence and Margin Expansion

    Adjusted gross margins improved by 120 basis points underlying to 62% in Q2, benefiting from an $8 million tariff refund and operational productivity. Adjusted EBITDA margin improved by 70 basis points underlying to 17.9%. The company is focused on optimizing its operating model through initiatives like EGX and consolidating production facilities in lower-cost locations, expecting multi-year margin expansion. Investments in R&D have also stepped up to support future growth.

    04

    Financial Discipline and Capital Allocation

    Enovis has made significant progress in financial discipline, moving from negative to positive free cash flow in the first half of FY26, with Q2 FCF at $31 million. Leverage has been reduced to 3.1 times, and the balance sheet refinanced. The company aims to bring leverage below 3x by year-end. With the Lima integration costs stepping down, Enovis is beginning to evaluate portfolio advancements for long-term growth while maintaining focus on cash generation and debt reduction, including potential divestitures and SKU reductions.

    05

    Market Dynamics and Headwinds

    The company faced several headwinds, including a 40 basis point impact to total growth from the Middle East conflict and softer markets in Western Europe (France, Spain, Italy) due to transient📎 environmental factors. Unplanned inflationary pressures, totaling $2 million in Q2 and an expected $10 million for the full year, are being actively mitigated. Despite these, the US ortho market remains stable, though with week-to-week volatility, and the company is confident in its ability to gain share.

    06

    ASC Strategy and Competitive Landscape

    Enovis views the ASC setting as a significant advantage due to patient and physician preference, favorable reimbursement dynamics, and opportunities for market share gains where contracts are less fixed. Products like Arvis are particularly well-suited for ASCs due to their mobility and economics. The company sees opportunities to attract talent and gain share amidst competitors experiencing disruption, leveraging its stable growth and nimble innovation.

    AI-generated summary of the company’s earnings call. Not investment advice.